Please login to the form below

Not currently logged in
Email:
Password:

Aveo

This page shows the latest Aveo news and features for those working in and with pharma, biotech and healthcare.

AVEO warns EU approval of Fotivda could be at risk

AVEO warns EU approval of Fotivda could be at risk

Concerns arose with overall survival data. AVEO Oncology has revealed in a regulatory filing that European Medicines Agency (EMA) approval for its Fotivda kidney cancer drug could be at risk of ... AVEO’s European licensee EUSA Pharma has been

Latest news

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – marketing &distribution. $171. AVEO Oncology/ CANbridge Life Sciences. AV-203; ErbB3 (HER3) inhibitory antibody for oesophageal cancer.

  • Deal Watch December 2015 Deal Watch December 2015

    405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Another early stage deal [opportunities do not seem to hang around long!] was that between Novartis and Aveo where Novartis paid an upfront fee of $15m to secure rights to AV ... Collaboration extension. 330. Aveo. Novartis. AV 380 antibody for

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Acquisition of voucher. 125. AVEO Oncology / Ophthotech Corporation. VEGF tyrosine kinase inhibitor tivozanib.

  • Pharma deals during February 2014 Pharma deals during February 2014

    In another termination of an oncology deal, Astellas exercised its right to terminate its collaboration with Aveo Oncology to develop the tyrosine kinase inhibitor, tivozanib, for “strategic reasons”.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance

    He joins the biopharma from Tang Capital Management. AVEO Oncology has appointed Dr Nikhil Mehta as senior vice president or regulatory and quality assurance, a role that will see him oversee ... I anticipate Dr Mehta’s integration into the AVEO team

  • AVEO's financial head joins ImmunoGen AVEO's financial head joins ImmunoGen

    David Johnston appointed chief financial officer. David Johnston has left his role as chief financial officer of AVEO Pharmaceuticals to join ImmunoGen in the same role. ... Johnston's switch comes after more than six years at AVEO having joined the

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics